You are here

Article Text

Article menu

Download PDFPDF

E-Poster Presentations
P02 Microbiome and Immune System/Immunotherapy
P02.03 Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma
Free
  1. E Staib1,
  2. K Leuchte1,2,
  3. M Thelen1,
  4. P Gödel1,2,
  5. A Lechner3,
  6. P Zentis4,
  7. M Garcia-Marquez1,
  8. D Waldschmidt5,
  9. RR Datta1,6,
  10. R Wahba6,
  11. C Wybranski7,
  12. T Zander2,
  13. A Quaas8,
  14. U Drebber8,
  15. DL Stippel6,
  16. C Bruns6,
  17. K Wennhold1,
  18. M von Bergwelt-Baildon9,10 and
  19. HA Schlösser1,6
  1. 1Center for Molecular Medicine Cologne, University of Cologne, Köln, Germany
  2. 2Department I of Internal Medicine and Center for Integrated Oncology (CIO) Aachen Bonn Cologne Duesseldorf, University Hospital Cologne, Köln, Germany
  3. 3Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital, LMU Munich, Munich, Germany
  4. 4Cluster of Excellence in Aging-Associated Disease, Core Facility Imaging, University of Cologne, Köln, Germany
  5. 5Department of Gastroenterology and Hepatology, University Hospital Cologne, Köln, Germany
  6. 6Department of General, Visceral and Cancer Surgery, University Hospital Cologne, Köln, Germany
  7. 7Department of Diagnostic and Interventional Radiology, University Hospital Cologne, Köln, Germany
  8. 8Institute of Pathology, University Hospital Cologne, Köln, Germany
  9. 9German Cancer Consortium (DKTK), Heidelberg, Heidelberg, Germany
  10. 10Department of Internal Medicine III, University Hospital, LMU Munich, Munich, Germany

Abstract

Background Thermal ablative therapies, such as microwave ablation (MWA) or radiofrequency ablation (RFA), are standard treatments for HCC. In addition to the local tumor destruction, abscopal effects (a reduction of a tumor mass in areas that were not included in the thermal ablation) could be observed. These systemic effects may be mediated by anti-tumor immune response, which has been described for RFA. MWA is rapidly replacing RFA, but systemic immunostimulatory effects of MWA treatment have been poorly studied.

Materials and Methods Patients receiving MWA for localized HCC were included in this study. Effects of MWA on peripheral blood mononuclear cells (PBMC) of HCC patients treated with MWA were analyzed by multicolor flow cytometry. Tumor-specific immune responses against 7 shared tumor antigens were analyzed using peptide pools in 3-color Fluorospot assays (Interferon-y/Interleukin-5/Interleukin-10). The impact of type, density and localization of tumor-infiltrating lymphocytes was assessed by immunohistochemistry (IHC) of CD3, CD4, CD8, FoxP3, CD38 and CD20 and digital image analyses (Immunoscore) of tumor specimens in an additional cohort of patients who received combined surgical resection and thermal ablation.

Results While comprehensive flow cytometric analyses in sequential samples (day 0, 7 and 90) of a prospective patient cohort (n=23) demonstrated only moderate effects of MWA on circulating immune cell subsets, Fluorospot analyses revealed de novo or enhanced tumor-specific immune responses in 30% of these patients. This anti-tumor immune response was related to tumor control. Interferon-y and Interleukin-5 T cell responses against cancer testis antigens were more frequent in patients with a long-time remission (>12 months) after MWA (7/16) compared to patients suffering from an early relapse (0/13 patients). Presence of tumor-specific T cell response (Interferon-y and/or Interleukin-5) was associated to longer progression-free survival (15.0 vs. 10.0 months). Immunohistochemical analyses of resected tumor samples revealed that a high T cell infiltration in a second tumor lesion at the time of thermal ablation was associated with superior disease-free survival (37.4 vs. 13.1 months).

Conclusions Our data demonstrates remarkable immune-related effects of MWA in HCC patients. This study and provides additional evidence for a combination of thermal ablation and immunotherapy in this challenging disease.

Funding ‘Koeln Fortune’ and ‘CAP-CMMC’ local research grant (to P.G. and H.A.S.) supported our research.

Disclosure Information E. Staib: None. K. Leuchte: None. M. Thelen: None. P. Gödel: None. A. Lechner: None. P. Zentis: None. M. Garcia-Marquez: None. D. Waldschmidt: None. R.R. Datta: None. R. Wahba: None. C. Wybranski: None. T. Zander: None. A. Quaas: None. U. Drebber: None. D.L. Stippel: None. C. Bruns: None. K. Wennhold: None. M. von Bergwelt-Baildon: None. H.A. Schlösser: None.

https://doi.org/10.1136/jitc-2020-ITOC7.39

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.